BFC Planning’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
Other funds holding MLTX
BFC Planning's MLTX Position: Q3 2026 in Review
BFC Planning opened a new position in MoonLake Immunotherapeutics (MLTX) in Q3 2026: 3 shares worth $35. The stake represents ﹤0.01% of the portfolio and ranks #3429 among its holdings.
106 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.
- BFC Planning held 3 shares of MoonLake Immunotherapeutics worth $35 as of Q3 2026.
- MoonLake Immunotherapeutics was a new BFC Planning position in Q3 2026.
- MoonLake Immunotherapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3429 holding.
- 106 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.